An Integrated Cancer Treatment program
In our way of treating cancer, we strive to combine the best from both the traditional western medical approach with natural and holistic treatment perspectives. We are always updating our knowledge, and put all the new scientific discoveries we find on our scientific website www.medicdebate.org, where everyone is invited to help us keep track of all interesting new medical discoveries.
Many of the most common cancers found in our society have been traditionally rare in other large populations in the world; studies of migrants exclude a simple genetic explanation for these wide geographical variations and imply that psychological and environmental exposures are key determinants of the development of these cancers.
Our basic vision is that the most important issue for each patient is to learn how to connect to his/her inner core, and learn how express that more and more, in order to create a life worth living, with lots of fun, love, creativity, healthy good food and meaningful interpersonal relationships.
We strongly recommend patients to engage in hobbies and creativity. It is never too late to start learning how to play that music instrument you were always dreaming to master, start painting, or writing the novel you always wanted to write. If you already are engaged in hobby activities, bring you music instrument, knitting set or painting gears with you. If not, we will do our best to provide you with whatever you need to enhance your creativity. It is much better to be engaged in positive and creative activities the being a conventional cancer patient, only waiting for next treatment, worrying and reading about cancer. We actually advice our clients to avoid all reading and other activities connected to cancer. It is our work to be updated and provide the best treatment available. We wish our clients to focus there entire attention on enjoying their lives and be as loving, loved and creative as possible.
There is overwhelming scientific evidence that exercise has a cancer preventive effect and also a positive effect on cancer survival. We encourage all our clients to have daily exercise. We have connections to a fully equipped gym, tennis courts and swimming-pool and have excellent walking possibilities in the surrounding forests and hills. We also provide yoga classes, physiotherapy and massage.
Many of today’s most challenging, costly and debilitating chronic disease conditions – including heart disease, Type II diabetes, obesity, osteoporosis, digestive and autoimmune disorders as well as many types of cancers – have been demonstrably linked to suboptimal nutrition.Optimal nutrition creates a foundation all the way down at the cellular level for a strong and healthy body. Through understanding the relationship between our external environment (I.e. the food we ingest) and our internal environment (cellular function fuelled by nutrient absorption).
we are able to achieve the complete, balanced nutrition essential to ensuring the harmonious system functioning that is at the core of what we think of as good health. Our program recognizes that restoring nutritive balance is an essential part in order to promote healing in a body that is stressed by the burden of invasive chronic illness.
In most westernised societies, modern food production, processing and transport technologies as well as lifestyle have combined to create an environment in which convenience and preservation have largely replaced nutritional content as the dominant selection criteria driving food choices. The unintended consequence has been a negatively charged version of “We are what we eat”; without a doubt, this modernization of our food supply chain has resulted in critical nutritional deficits that at minimum prevent optimum health, and may promote or even accelerate disease progress.
Your treatment program approaches nutrition from a healing perspective, approaching food as medicine. As a patient you will be “prescribed” with nutrition plan based on your unique needs, with special special attention to identifying and addressing deficiencies, higher nutritional needs, and allergies – some you may not even be aware of having – as well as taste and appearance. We co-operate with some of the worlds most advanced food allergy and hormone laboratories in the US and also do determine correct assessments analysis with the help of dark field dark field microscopy and dried layers tests.
A ketogenic diet is one in which carbohydrates, and to a lesser extent, protein are restricted in the diet and replaced with fat. This treatment has been effective for seizure control in epileptic children for over a century and more recently for the treatment of obesity-related disorders. It may also provide a benefit in cancer subtypes with outcomes closely related to obesity and metabolic risk factors, such as breast cancer. It generally implements a ratio of 4:1 fat to protein and carbohydrates. However, many people will reach significant ketosis when their carbohydrates are limited to less than 50g per day, and others at around 20-30g.
What are Ketones?
Ketones are energy sources produced by our liver that can freely cross our blood brain barrier to provide a source of energy for our neurons (brain cells). These ketones replace glucose when it is not available, such as during fasting, during the winter months in traditional societies, and all the time in modern hunter-gatherer societies like the Inuit Eskimos or Maasai tribesmen, who consume very little carbohydrate sources.
One way of empowering a ketogenic diet is the Budwig Protocol. Basically this involves consuming as much flax seed oil blended with zero fat quark as you can. When you blend the two together with a hand blender the oil actually binds to the protein in the quark. The oil then gradually replaces all the bad fats that may have got lodged in your cell walls, making them healthier and more alkaline. There is also a very helpful free download book from the Budwig Centre. Http://www.budwigcenter.com/budwig-guide.php
For many cancers, the most common cause of death is lack of protein = starvation. MAP is a dietary protein substitute that provides the MAP Master Amino Acid Pattern® a unique pattern of essential amino acids in a highly purified, free, crystalline form. 1. MAP™ provides a 99% Net Nitrogen Utilization (NNU). This means that 99% of MAP's constituent amino acids act as precursors for BPS to become body’s constituent proteins. By comparison, the most nutritious dietary proteins, such as meat, fish or poultry provide an average of 32% NNU. Consequently, only 32% of their constituent amino acids can act as precursors for BPS. Meanwhile, most protein supplements only provide an average of 16% NNU, because they use milk, soy, casein or whey as their primary protein source. As a result, only 16% of their constituent amino acids act as precursors for BPS. Therefore, dietary proteins provide a BPS that is at least 3 times lower, compared to MAP™. While, protein supplements provide a BPS that is at least 6 times lower, compared to MAP. MAP is absorbed in the small intestine within 23 minutes from its ingestion. By comparison, dietary proteins and protein supplements need from 3 to 6 hours to be digested. This is 6 to 12 times longer compared to MAP™. If you are a cancer patient, You often have problems absorbing nutrients and breaking down proteins. MAP will help against this problem. MAP releases only 1% nitrogen catabolites, namely metabolic toxic waste. By comparison, dietary proteins and protein supplements release an average of 68-84% nitrogen catabolites. This is 68 to 84 times more metabolic toxic waste compared to MAP™. Therefore by taking MAP™ in substitution of dietary proteins or protein supplements, overloading of the liver and kidney functions may be prevented. Thus, a healthier and more effective physical activity may be achieved.
The liver is normally to a large extent occupied in turning proteins into calories, and will be greatly relieved when not being bombarded by unusable proteins These Nitrogen Catabolites can also have a toxic effect on the nervous system.
Big investigations published in major medical journals have proven that cancer could be reduced 50% in the norhern countries if people had enough Vitamin D. High dose Vitamin D have also been proven to prolong survival for prostate cancer and many other cancers. The best source for Vitamin D is the Sun. 30 minutes sunbathing in the summer is enough, even for a cancer patient. Unless you can do this, we recommend 5-10 000 ie/ day (125-250 microgram). Vitamin D is also very important for those who takes GcMAF, which will be mentioned further down in the article.
Dr Frederick B Levenson began his work with cancer patients in 1974, when he started providing psychotherapy for a stage IV breast cancer patient, with the primary goal of aiding her capacity to regulate and discharge irritation. To his astonishment, he discovered that the patient started to recover from her cancer, as she connected more and more to Dr. Levenson in the psychotherapeutic process. In the end, she was totally free from cancer. He discovered that she was not the only one who could be healed from cancer by using this method, and over the years he refined his techniques, with even better results as a consequence. In 2010 a review was published of of Dr Levenson’s records and the medical records of his patients during a 35 year period. This clearly demonstrated a positive effect on patient longevity and both observed and reported patient quality of life.
In this paper 75 cases treated during 1974 to 2008 were discussed. Almost all patients were diagnosed with “incurable” cancers treated by oncologists at esteemed medical centres. All subjects within this sample, with the exception of two who died immediately after the initialisation of treatment experienced an improved quality of life according to case records and reviewed documentation; 33 (44%) are still alive, 80% survived for more than five years and 45% survived for more than 10 years. A noticeable trend of improved patient quality of life and longevity had occurred as Levenson refined and improved his treatment methodology over the decades. The patients often sought treatment after a terminal diagnosis, having been informed that allopathic biomedical interventions could not alter their prognosis. There seemed to be an improvement in longevity and several spontaneous remissions were noted in the hospital documentation. The basic principle of Levenson Therapy is that cancer is not seen as a disease, but as a process, that can be reversed. Everyone has cancer cells in his/her body all the time, but normally these cells are taken care of by the immune system, so that no serious problems will develop. Cancer cells are embryonic cells that do not complete their maturation process into fully differentiated, adult cells, and Dr Levenson postulates that the reason for this lack of maturation of certain cells lies in early traumas, and lack of adequate emotional support in early childhood as well as later in life.
In order to heal these often very early wounds and personality patterns, it is necessary to let the therapist become like a surrogate mother, who “adopts” the patient in order to give support through two 45 minute talks a week plus daily contact over the telephone for a couple of minutes. It is also always possible to call the therapist 24/7 in emergency situations. If you cannot come to the therapist physically, sessions can be performed over a land-line telephone or Skype.
Dendritic Cell Immunotherapy (DC-Therapy)
The immune system helps you stay healthy by identifying bacteria and viruses as foreign and killing them. Over the last ten years it has emerged that antigen presenting cells are needed for the detection of foreign materials (known as antigens). Antigen presenting cells alert the immune system to the presence of intruders and activate other immune cells, which neutralize the antigen by various means. The most important antigen presenting cells are dendritic cells. Dendritic cells have tree-like appendages, known as dendrons, (Greek dendron = tree) with which they search for foreign materials on their way through lymphatic fluids and the blood.
Cancer cells are also distinct from healthy cells. This difference, the degree of “foreign”, is used in immunotherapy to combat the cancer with the body’s own defense mechanisms. So far the patient's cancer evaded the anti-tumor action of the immune cells. However, new research has shown that the immune system can be given a second chance if it is helped to recognize the cancer as foreign.For this the patient´s own blood cells (specifically the sub-group monocytes) will be grown in the laboratory by adding cellular messengers called cytokines. Monocytes are a type of white blood cell (leucocytes) that are usually only present in small amounts in the body. From these cells a vaccination will be manufactured which will activate the immune system against the tumor. Your “educated” antigen presenting cells will be administered into your body (by injection into the skin or veins) to vaccinate against the cancer. They will enter a lymph node via the blood and lymph vessels to either trigger a new immune response or to enhance a weak response that might already be present.
Second Opinio Clinic has just started a co-operation with the “Praxisgemeinschaft fûr Zelltherapie in Duderstadt, germany, where we can provide therapy with Dendritic cell vaccine and many other immune therapies like Newcastle disease virus and Gamma Delta cells.
Newcastle Disease Virus (NDV)
With regard to the up to now unfavorable results of conventional therapy in the treatment of especially advanced tumors novel therapeutic methods have to be developed. Beside dendritic cell therapy another promising approach is the treatment with replication-selective viruses, also called oncolytic viruses. This approach is also known as virotherapy. The approach to virotherapy in our group is based on the Newcastle Disease Virus (NDV), one of the most promising candidates among the group of oncolytic viruses. NDV belongs to the family of the paramyxo viruses. NDV is not a pathogen for humans and is absolutely harmless causing only mild-flu-like symptoms or conjunctivitis in the worst of cases. NDV replicates efficiently in humans in tumor cells, only leading to complete destruction of the infected tumor cells within a short time. In clinical studies with NDV carried out so far, significant tumor remissions as well as prolonged survival periods have been observed with a very low rate of observed side effects. The Newcastle Disease Virus, which is used in our group for virotherapy, is propagated on human tumor cell lines and kept in high-pure form by means of a newly developed cleaning method by Prof. Dr. Dr. Lüke from the German Primate Center in Göttingen (DPZ). The oncolytic potential of NDV is highly increased by the additional application of local hyperthermia before the administration of NDV, and by vaccination with Dendritic cells afterwards.
Onkolytic viruses and lytic effect on cancer cells
The application of viruses for cancer treatment is based on reports since the beginning of the 20th century on temporary improvement of cancer following natural viral infections or vaccinations against viral diseases. Using animal models the lytic effect of certain viruses on tumor cells was demonstrated at the beginning of the 1950. Modern techniques in molecular biology give rise for the development of oncolytic viruses as efficient treatment modality in human cancer. Base on the scientific knowledge an oncolytic virus should be based on three main features:
1. The virus selectively targets neoplastically transformed cells and leave normal cells uninfected.
2. The virus is replication competent and can destroy his host tumor cell.
3. The virus induces only mild to moderate side effects.
Viruses with RNA as genetic material are potent candidates within the viruses tested for the above mentioned features. Especially NDV shows a natural distinct tropism for cancer cells based on the fact that the most of the tumor cells are more or less unable for an effective virus defense. NDV is an enveloped virus with two main virus specific glycoproteins found in the envelope, which are required for initial binding to and entering of NDV in the host cell. In humans, oncolytic NDV selectively replicates in human tumor cells whereas non neoplastic cells remain uninfected. Cancer cells infected with NDV can be killed directly by the virus within a short time after infection or leads to induction of a specific immunresponse against the virus infected cancer cell. The virus is non pathogenic in humans. The ability of NDV to infect and replicate efficiently in human cancer cells has been demonstrated by laboratory and animal studies. The ability of NDV to kill human cancer cells in vivo has also been shown.
Clinical studies with NDV
In 1965, Casell and Garett first used NDV to treat a human cancer, applying it intratumorally on one patient with a cervical carcinoma. A remarkable tumor regression was observed. Meanwhile NDV-based anticancer therapy has been reported to be of benefit in more than a dozen clinical studies concerning various tumor types. The studies prove to be a powerful weapon especially against the most malignant brain tumor, glioblastoma multifome WHO IV.
So far, two main different approaches for NDV based cancer therapy have been developed:
Treatment of cancer patients with NDV
Treatment of cancer patients with oncolysates, which are preparations containing plasma membrane fragments of NDV infected cancer cells (autologous or allogenic).
The reported side effects associated with NDV exposure have generally been described as mild to moderate causing mild flu-like symptoms (fever), sometimes inflammation at the injection site and conjunctivitis in the worst of the cases. NDV can be administered intratumorally, intravenously as well as by inhalation.
The first research was done in 1988 by professor Marco Ruggiero, and since then over 46 research papers have been published by over 100 scientists indicating that GcMAF rebuilds the immune system, and the immune system then eradicates early stage cancer and other diseases.
How does GcMAF work? In a healthy person your GcMAF acts like the “commanding officer” of your immune system and also instructs macrophages in your bloodstream to scour our bodies and kill malignancies. But malignant cells like cancer send out an enzyme called Nagalase that neutralises your GcMAF; so the macrophages never get the message to go into action – in this way disease suppresses the immune system, and cancer cells grow unchecked. In its role of immune system regulator, research shows GcMAF can reverse diseases that attack the immune system like chronic inflammation, bacterial and viral infections, Autism, Chronic Herpes, Chronic Acne, CFS, XMRV, Lyme disease, AIDS, HIV, Fibromyalgia, osteoporosis, Hodgkin’s, Lupus, MS, Parkinson’s, and various types of Immune dysfunction.
There have been excellent results on cancer treatment from the GcMAF group led by professor Marco Ruggiero with the so-called Swizz protocol: Below is a citation from their website, www.gcmaf.eu
1. For stage one, a standard dose of 0.25ml GOleic twice a week, for stage 2 three doses a week, late stage 4 up to a full 1ml a day. The more the better. 2ml a day has been taken without side effects.
2. 10,000iu of vitamin D a day,
3. Eat white meat, fish and vegetables,
4. No sugar or carbohydrates (so no cereals or bread etc) which feed cancer.
5. If your weight drops below your perfect weight for your height, take Branch Chain Amino Acids (BCAA) from a vitamin shop, or better, Master Amino Acid Pattern (MAP) from Dr Reinwald Healthcare.
If you add drugs to this, the more you add the more you will reduce your chances of success. More is less.
Don’t stop the Goleic until 8 weeks after you have scans proving you are cancer free, or 8 weeks after your nagalase drops below 0.65.
We are just as successful with pancreatic cancer, and with our two multiple myeloma cases, but it takes doses of two ml a day initially. We’ve done laboratory experiments on leukemia which indicate we should get good results, that too will need 2 ml doses, but chemotherapy can make blood and immune system counts so low treatment fails.
Avoid the five main causes of cancer
1. Too much sugar
2. Lack of vitamin D3
2. Poor nutrition lacking in amino acids and trace metals,
4. Lack of oxygen and exercise,
5. Severe shock stress.
From GcMAF’s discovery in 1990 until 2013, 0.25ml of GcMAF a week was recommended, because it was thought GcMAF only rebuilt the immune system and activated macrophages, where it has a half life of 6 days. In 2013 we carried out laboratory research and published research papers (See “the Science” here) in which we discovered four more attacks GcMAF/Goleic has on cancer, three excellent results on the brain, and two on cells. These have a half life of 3 days. Coupled with feedback over four years, we’ve now re-adjusted the dosing. So for cancer we now suggest at least two 0.25 doses a week, which is enough for good responders. In our Treatment Centres the maximum we give is 4ml, two vials a day for 2 days only, because the body cannot transport cancer debris away at that level. The most we give continually is 2ml a day.
If you are treating an infection or a cold, give one 0.25-0.5 shot only. It may be gone in 36 hours. If you take shots every day, the immune system will be kept high, producing mucous and maintaining the symptoms long after the cold should have left.
Stay away from: sugar, which feeds cancer, carbohydrates which turn into sugar; and grains beans and potatoes, which also contain cancer inducing lectins and poisons – wheat is the worst. Avoid soya milk which blocks the absorbance of trace metals.
Some sweeteners are damaging in other ways – asparthame lowers your immune system; even Splenda is a chlorocarbon like DDT – See http://www.wnho.net/splenda_chlorocarbon.htm.
The best appears to be the natural plant sweetener Stevia, to which they add relatively harmless maltodextrin for supermarkets. Second best is saccharin.
If you have a root canal, you are advised to have that tooth removed. (See article)
Avoid molybdenum, which makes breast cancer grow. The richest sources of molybdenum are legumes, including beans, peas, lentils and soybeans. Nuts, leafy vegetables and grains like oats, wheat and rice also contain ample amounts.
And ordinary milk contains estrogen, which is a growth factor for uterine cancer, and for breast cancer but less so.
Stage 4 cancer
GcMAF has six attacks on cancer; four direct, where its half life is three days. So most importantly increase the GcMAF dosage, and put into different parts of the body at least twice a week. As a macrophage activator its half life is 5 days (the half life of macrophages is 6 days). These 5 attacks start up in within minutes. You can see the increase in activity in the spleen on live scans. The sixth attack, the immune system, is fully rebuilt by GcMAF in 3 weeks. IV by a doctor is best.
Ask to come to our residential Treatment Centre in Switzerland where we use ultrasonography to accurately measure your tumors, and to place the GcMAF in the right place. We re-measure a week later and expect a 25% reduction in the first week.
If you can have surgery to reduce tumour mass, do so, but make sure you are on GcMAF for at least three weeks before the surgery, so that your rebuilt immune system can prevent secondaries caused by cancer cells released by surgery settling elsewhere.
And then keep the GcMAF up for 8 weeks after scans show your tumours are gone, or nagalase first drops below 0.65."
I have several case with complete resolution of stage 4 cancer tumors, but my patients have been using the home protocol, so I have not seen anything like 25% tumor reduction a week yet. For me, 25% tumour reduction per year is more than enough, compared to 0 % reduction, and most likely, tumor progression and death.
At the ASCO(American Society of Clinical Oncology) congress in Chicago from June 4th to 8th 2010, the world’s most prestigious congress of clinical oncology with 30 to 35,000 participants, was published on the poster section a rather sensational result in the treatment of non-small cell lung cancer with an increase of five year survival from an expected <1% to 44%!! There are also extremely good results in the treatment of pancreatic cancer, liver cancer, gallbladder cancer, stomach cancer and oesophageal cancer.
Psorinum is an alcoholic extract of scabies, slough, and pus cells. According to the pre-clinical data, “Psorinum-6x” (“x” stands for decimal potency of homoeopathy) activates different immune effector cells (e.g., T cells, and accessory cells like, macrophages, dendritic cells, and natural killer cells) which can trigger a complex antitumor immune response .
In an observational, open level and single arm study on158 patients with histologically confirmed stomach, gall bladder, liver and pancreatic cancer, complete tumour response occurred in 28 (17.72%) cases and partial tumour response occurred in 56 (35.44%) of cases The participants’ eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumour, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were to assess the radiological tumor response to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homoeopathic supportive cares. There were 42 stomach cancers, 40 gall bladder cancers, 44 pancreatic cancers and 32 liver cancers included in the final analysis of the study.
In this study, no adverse side effects were observed from the drug Psorinum. However, very few patients reported to have mild oral irritation and skin itching which were successfully controlled by the supportive cares. Psorinum Therapy was also effective in improving the disease symptoms and the quality of life of the participants. At least 60% participants of stage-III and at least 45% participants of stage-IV reported that the therapy was effective in reducing their cancer-related pain, cough, dyspnoea, nausea and vomiting, fatigue, constipation and improving appetite, and weakness. These were also confirmed after examining the participants clinically. Improvements were also observed in the lab investigations like Complete Blood Count (CBC), Liver Function Test (LFT), Kidney function test, AFP level, and CA 19.9. These lab investigations were done as a part of their routine clinical check ups. Among the 158 participants, 98 (62.03%) were aged 65 years or more. Better outcomes were observed among the participants below 65 years of age than the participants who were over the age of 65. The outcomes did not vary significantly while considering gender.
The cumulative 5-year survival was 39.24% for patients who received Psorinum treatment, compared with an estimated 5-year survival of 23% for stomach cancer, 10% for liver cancer, <4% for pancreatic cancer and <15% for gall bladder cancer for patients taking conventional therapies. 28 patients (17.72%) had a complete recovery from their cancer in this study.
Psorinum in the treatment of Non Small Cell Lung Cancer(NSCLC) In another phase II, open-level, single arm, and single stage study, also performed by Dr Chatterje et al, 95 participants were included with NSCLC. According to the AJCC TNM staging system, 58 (61.05%) of them diagnosed at stage IV. According to the RECIST criteria, complete tumour response occurred in 19 (20%) cases and partial tumour response occurred in 28 (29.47%) cases. 82 (86.32%) of them survived at least 1 yr, 70 (73.68%) survived at least 2 yrs, 58 (61.05%) survived at least 3 yrs, 49 (51.58%) survived at least 4 yrs, and 42 (44.21%) of them survived at least 5 yrs. These participants did not receive chemotherapy, radiation therapy, or any other investigational cancer treatments. Participants reported no side effects from the drug Psorinum.
Regarding pancreatic cancer:
44 patients participated in the study with Psorinum D6, 0,02 ml per kg body weight in the morning on empty stomach. Survival after first year 34, after 2 years 28, after 3 years 27, after 4 years 21, and after 5 years 17 of the patients were still alive, equal to a 5-year survival of 39% - Probably the highest ever recorded 5 year survival on Pancreatic Cancer published so far in medicine history!! These results were examined by a very critical an independent expert commission at the National Cancer Institute in Bethesda, near Washington DC, USA, who has accepted the results, so that Dr. Chatterjee was able to present the results at the ASCO conference. There are plans to make more research on Psorinum on the famous MD Anderson Cancer Institute in Houston, Texas, USA
The treatment is suitable for many more cancer types, but research has so far been focused on the more difficult cancers.
Dosage: 20 drops/day if you are 50 kg, 30 drops if ypu are 75 kg etc. You can also divide the dose into several daily dosis if it is too much to swallow at once. Take it on empty stomach and keep in the mouth for a while before swallowing.
Already in the early 1940s, it was discovered that leukaemias and sarcomas in rats can be healed and prevented by adding certain amino acids and trace elements to their diets. Prof Thomas Tallberg from Helsinki continued to develop these research findings into therapeutic modalities available for treatment of human cancers. He also found that when cancer cells receive these amino acids and minerals, their respiratory organs, or mitochondria, change shape and become dense with electrons. The next thing that happens is that the cancer cells transform into normal cells. This means that he has found a method which can correct the metabolic aberration in certain cancer cells, so that they can stop being cancer cells and continue their natural differentiation into normal cells. In many cases, he has thus managed to heal skin tumours in both animals and humans without even leaving a scar!!He has published controlled clinical studies showing how, among other things, he completely healed 60% of stage 4 malignant melanomas, 90-100% of melanomas of the eye (uveal melanomas) and 30% of stage 4 kidney cancers, conditions that are normally almost 100% lethal. He has so far found the formulae for treating malignant melanomas, breast, prostate, kidney and gastrointestinal cancers with great success. He can also treat psoriasis with this method with an almost 100% success rate.
Besides taking one or two scoops of amino-acid/mineral powder each day, Dr Tallberg also recommends a small amount (50 g) of mammalian brain each day. According to Tallberg, this has the dual effect of boosting the immune system and providing a balanced intake of essential lipids. He himself sells cans of piglet brain pate, that can be used as spread on bread, mixed with ice cream or served as a dessert resembling pina colada.
He also uses a special kind of autologous vaccine, made from the patient’s own tumour tissue, and recommends avoidance of certain types of food nutrients for different types of cancer that can stimulate cancer growth, I.e. molybdenum for breast cancer patients and zinc for kidney cancer patients.
We can provide the Tallberg protein/mineral powders and mammalian brain and we have plans to create a laboratory for making the autologous cancer vaccines.
Currently, these vaccines cannot be made anywhere on planet earth except in Tallberg’s own laboratory, and as he is presently 77 years old, he is trying to reduce his workload, and therefore does not accept new patients.
You can order breast formula, stomach formula, prostate formula and skin formula from www.gaya-nutrition.com.
Conventional Cancer Therapies
Metronomic chemotherapy is one of the biggest steps forward in the history of cancer treatment and is based on the understanding of the blood supply in cancer tissue, or rather the possibility of controlling this so that the cancer cannot grow. For patients, this new method of treatment is very interesting because it has practically no side effects. The treatment primarily uses tablets and research shows that this gives results that are as effective as conventional chemotherapy, in which the highest possible doses are given every second or third week, most often with quite serious side effects. Angiogenesis means the creation of new blood vessels from an existing blood vessel and this is the primary way in which cancer cells obtain nutrition. Normal chemotherapy also destroys the endothelial cells in the small blood vessels, but is normally interrupted 2-3 weeks between treatment in order to let the body recuperate form serious side effects like nausea, vomiting, bad immune system and diarrhoea. During this time the cancer rebuilds its blood supply. Metronomic chemotherapy, just like the regular beat of a metronome, is given daily or every second day, and thus does not allow the blood vessels to re-establish. It does not matter which type of cancer cells are involved or even whether they have become resistant. It is not cancer cells themselves which are attacked by metronomic therapy, but the blood vessels supplying the cancer cells. You may be wondering whether the endothelial cells, too, can become resistant in the long run – and the answer is yes. However it takes a much longer time for the cancer cells to become resistant and the normal process under metronomic treatment is likely to be as follows: At first the tumour becomes smaller, then comes a long and stable period which can last for years until finally the cancer grows again. You can then shift to another form of metronomic chemotherapy or a combination of metronomic substances.
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. Because scientists often call these molecules “molecular targets,” targeted cancer therapies are sometimes called “molecularly targeted drugs,” “molecularly targeted therapies,” or other similar names. By focusing on molecular and cellular changes that are specific to cancer, targeted cancer therapies may be more effective than other types of treatment, including chemotherapy and radiotherapy, and less harmful to normal cells.
Below are some examples of targeted therapies: Imatinib mesylate (Gleevec®) is approved to treat gastrointestinal stromal tumor (a rare cancer of the gastrointestinal tract), certain kinds of leukemia, dermatofibrosarcoma protuberans, myelodysplastic/myeloproliferative disorders, and systemic mastocytosis.
Trastuzumab (Herceptin®) is approved for the treatment of certain types of breast cancer as well as some types of gastric or gastroesophageal junction adenocarcinoma.
Lapatinib (Tykerb®) is approved for the treatment of certain types of advanced or metastatic breast cancer.
Gefitinib (Iressa®) is approved to treat patients with advanced non-small cell lung cancer.
Erlotinib (Tarceva®) is approved to treat metastatic non-small cell lung cancer and pancreatic cancer that cannot be removed by surgery or has metastasised. This small-molecule drug inhibits the tyrosine kinase activity of EGFR.
Cetuximab (Erbitux®) is a monoclonal antibody that is approved for treating some patients with squamous cell carcinoma of the head and neck or colorectal cancer.
Everolimus (Afinitor®) is approved to treat patients with advanced kidney cancer whose disease has progressed after treatment with other therapies, patients with subependymal giant cell astrocytoma who also have tuberous sclerosis and are unable to have surgery, or patients with pancreatic neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasised.
Bortezomib (Velcade®) is approved to treat some patients with multiple myeloma. The drug is also approved for the treatment of some patients with mantle cell lymphoma.
Bevacizumab (Avastin®) is a monoclonal antibody that is approved for the treatment of glioblastoma. The therapy is also approved for some patients with non-small cell lung cancer, metastatic colorectal cancer, and metastatic kidney cancer.
Sorafenib (Nexavar®) is a small-molecule inhibitor of tyrosine kinases that is approved for the treatment of advanced renal cell carcinoma and some cases of hepatocellular carcinoma.
Sunitinib (Sutent®) is another small-molecule tyrosine kinase inhibitor that is approved for the treatment of patients with metastatic renal cell carcinoma, gastrointestinal stromal tumour that is not responding to Imatinib, or pancreatic neuroendocrine tumours that cannot be removed by surgery, are locally advanced, or have metastasised. Sunitinib blocks kinases involved in VEGF signalling, thereby inhibiting angiogenesis and cell proliferation.
Rituximab (Rituxan®) is a monoclonal antibody that is approved to treat certain types of B-cell non-Hodgkin lymphoma and, when combined with other drugs, to treat chronic lymphocytic leukemia (CLL). The therapy recognizes a molecule called CD20 that is found on B cells. When Rituximab binds to these cells, it triggers an immune response that results in their destruction. Rituximab may also induce apoptosis.
Ipilimumab (Yervoy™) is approved to treat patients with unresectable or metastatic melanoma. This monoclonal antibody is directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), which is expressed on the surface of activated T cells as part of a “checkpoint” to prevent a runaway immune response. By inhibiting CTLA-4, Ipilimumab stimulates the immune system to attack melanoma cells.
Catumaxomab (Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in patients with metastasizing cancer. It binds to antigens CD3 and EpCAM.
For patients with bone metastasis we use Biphosphonates such as Zoledronic acid (Zometa). These drugs stop the bones from being broken down by the cancer and also have some anti-cancer activity in their own right. We are mainly using a ‘metronomic’ dosage of Zometa, with a ¼ of the normal dose injected every week, instead of the full dose injected every month. In a clinical study from China, this dosage regimen has been proven to be better than the conventional schedule. Zometa is also used in order to stimulate the production of so-called Gamma-Delta cells, a typ of natural killer cells with the highest possible anti cancer activity in the immune system.
Conventional medicines with off-label anti cancer properties
LDN (low-dose naltrexone) Can boost the immune system — helping those with HIV/AIDS, cancer, autoimmune diseases, and central nervous system disorders. It also makes you feel better emotionally..
Noscapine, a naturally derived and existing ingredient of over-the-counter cough medicines in some countries, has also been shown to be useful against cancer. It works like the chemo drug paclitaxel (Taxol) but without many of the nasty side-effects.
Professor Lissoni from Italy has performed many clinical studies on the positive effects of taking 20 mg Melatonin at bedtime. It diminishes side -effects from chemotherapy, increases life quality and has also strong anti cancer effect son its own.
In order to fight cancer, it is very important to kill all other bacteria’s and fungal infections, that takes away the attention of the immune system from killing the cancer. Itraconazol is an anti-fungal medication, that besides killing fungi, also have a anti angiogenic effect, similar to metronomic chemotherapy, thereby cutting off the blood supply to cancer tumours.
Metformin is the drug of choice for the management of type 2 diabetes mellitus. It improves insulin resistance and glycemic control and can safely be combined with other classes of anti-diabetic agents. Exciting preclinical studies have shown that Metformin can inhibit the growth of cancer cells both cell culture tests and animal tests. The recent evidence that Metformin results in (a) initiation of an LKB1-mediated AMPK-dependent energy stress response that can adversely affect survival of cancer cell lines and (b) inhibition of cancer related genes and proteins like phosphoinositide 3-kinase/Akt/mTOR has provided a molecular basis for a direct, insulin-independent antitumor effect and strengthened the rationale to evaluate Metformin in cancer clinical trials.
The association of Metformin with reduced cancer mortality provides the rationale for the study of Metformin in the cancer treatment setting. A recent retrospective study in breast cancer patients showed that diabetic cancer patients treated with Metformin and neoadjuvant chemotherapy had a higher pathological complete response rate than the control groups. A phase III adjuvant trial of metformin is currently being launched by National Cancer Institute Canada and National Cancer Institute United States to assess the efficacy of Metformin in reducing breast cancer recurrence in 3,582 women with stage I and II breast cancer.
Recent studies have disclosed a surprising, but mechanistically consistent, anticancer activity of Disulfiram (Antabus), a drug used for about 50 years in the treatment of alcoholism. Disulfiram has been successfully used to suppress hepatic metastases originating from ocular melanoma.
The pharmacokinetics of Disulfiram and its pharmacological profile in cancer cell lines and in cancer cells obtained from patients is well known. Disulfiram is a readily available and inexpensive substance whose adverse effects are negligible, compared to classical cancerostatics.
Cancer creates a wound inside,( and sometimes also outside) the body. It then uses the bodies wound healing mechanism, which is inflammation, in order to increase the blood supply to the cancer itself. There are numerous studies showing positive effect of anti-inflammatory medicines on cancer survival. The most common anti-inflammatory medicines the so called NSAID medications like Aspirin, Diclofenak, Ibuprofen etc., the newer Cox 2 inhibitors like Celebra(Celecoxib) and Corticosteroids (Prednisone, Betapred etc.) We also use natural anti-inflammatory medicines like Boswellia Serrata(Frankincense), Turmeric, and Ginger.
Other Complementary Cancer Treatments
In Local Hyperthermia, you use a modulated electric field generated by two active electrodes . Since malignant tissue has higher conductivity than healthy human tissue, the electric field tends to flow predominantly through the malignant tumour tissue. The combination of deep layer heating and the electric field leads to stimulation of malignant tumour cells. This, in turn, triggers increased apoptotic activity in the tumour region and as a result, promotes cell death. Thanks to the selection at cellular level, the radiation only has an effect in the region of the tumour; the healthy regions remain as good as untouched.
In general, Local Hyperthermia can be used with all stages of cancer, although its current main use is with advanced solid tumours that are hardly operable or inoperable, as well as with recurrent tumours and metastases.
Also where conventional therapy approaches (surgery, chemotherapy, radiation therapy) are not very likely to be successful, or have proven to be inadequate, Local Hyperthermia has already been successfully used with the following tumours, including their metastases in different organs: Astrocytomas and glioblastomas, bronchial carcinomas, cervix carcinomas, colorectal carcinomas, carcinomas of the urethra, hepatocellular carcinomas, stomach carcinomas, malignant melanomas, mamma carcinomas, renal cell carcinomas, oesophagus carcinomas, ovarian carcinomas, pancreatic carcinomas, squamous epithelium, and carcinomas at head and throat.
Local Hyperthermia selectively heats the tumour tissue in the region to be treated. For this reason, Local Hyperthermia is particularly indicated for the treatment of localized solid tumours. It does not matter whether the tumour is located on the surface or deep down. The principle of self-focusing also allows moving regions of the body to be treated, such as the lungs, or thermo-sensitive regions such as the brain. Local Hyperthermia is effective both in areas with high blood flow, such as the liver, and in regions with high air circulation, such as the lungs.
Usually, the patient is treated for 1-1½ hour every second day. 10 such treatments are recommended.
High Level Full Body Hyperthermia
In high level full body hyperthermia, the body is heated for a few minutes to a temperature of 43-44 °C.
This is done with the patient in a bath tub with the assistance of an anaesthesiologist keeping the patient unconscious and under close medical supervision. The technology was developed in Novosibirsk, Russia, and has successfully treated thousands of cancer patients without any serious side effects.
WMCS (Wireless Micro Current Stimulation) is a new method for electrical stimulation of wounds. ES is recognized in more than 500 published articles as the most efficient method in wound care. The WMCS method transfers the electrical charges wirelessly to the wound, which makes the method significantly more useful than the previously known transferring methods.
The WMCS method uses oxygen to transport electrons to a ”plate out” effect on the wound, which means that the molecules deposits the electron, when they touch the wound or skin surface , while the oxygen molecule carries on as air gas. The basis for a current is the movement of electrons and with this simple method the WMCS technology transfers the current to the wound, where the so-called ”current of injury” is established and supports the natural bio-electrical process of the wound healing. WMCS has been proven to help the healing of cancer in many case reports. Dr John Wetling has invented a non-invasive electrothearpy can be bought www.wetling.dk.
Papimi device is a pulsed electromagnetic field generator. It is also related with bioresonance and frequency therapy. The produced nanopulses are characterized by high intensity and very short duration. The high power of the device and the unique way of function are the reasons of the wide range of applications and the remarkable results it shows. It is applied externally over the skin, by induction, (even over the clothes), painless, without any significant restrictions and without increasing tissues’ temperature. In addition no considerable adverse effects have been reported over the twenty-year application of the device.It has been used to treat sport injuries, cancer and many other diseases.
A root can be at the root of your problem!!
- Dental treatments
Today there are many studies that can demonstrate and scientifically prove how dental issues can create or be the root cause of systemic conditions or repercussions. Our goal is to determine the possible systemic relation if found with any undetected or previously established dental problems. Such dental disturbances can cause damage to the immune systems ability to fight cancer by diverting its energy to fight I.e. an untreated sub-clinic dental root infection. Mercury from old amalgam fillings and electric currents from these fillings and can also cause problems. If needed, we can refer our patients to qualified dentists for correction of these issues during their stay at the Second Opinion Clinic.
We use a wide variety of herbal treatments with scientifically proven anti-cancer properties. We can here mention Blood root, Sanguinaria Candensis, a plant use both internally and as the main ingredient in so called cancer salves, that has been used for treatment of cancer since many hundred of years with successful results. Bloodroot is often used for treatment of veterinary cancers. There are hundreds of scientific papers on the many strong and powerful anti-cancer effects of blood root.
Another anti cancer herb is milk thistle, Silybum marianum. It has been utilized for thousands of years to remedy a variety of ailments, particularly liver and gall bladder problems. Scientific studies suggest that substances in milk thistle (especially a flavonoid called silymarin) act to protect the liver from toxins, including certain drugs such as acetaminophen (Tylenol), which in high doses (or in combination with alcohol) can cause liver damage. Silymarin has antioxidant and anti- inflammatory properties, and is thought to help the liver repair itself by growing new cells.
Preparations from the European mistletoe (Viscum album L.) are among the most prescribed drugs in cancer patients in several European countries. The most common brand names are Iscador, Helixor and Viscum Album. Controlled Clinical Trials. In a randomized controlled study from 2008 on altogether 508 patients Iscador was shown to prolong overall survival of corpus uteri cancer patients. Psychosomatic self-regulation as a measure of autonomous coping with the disease, rised significantly more under Iscador therapy than under conventional therapy alone at a follow up of 12 months.
Treatment with HELIXOR proved to be beneficial for breast cancer patients since it significantly improved quality of life and significantly reduced persistent signs/symptoms of the disease/treatment during the validated after-care period of approximately five years in 167 patients treated with Helixor. In an open study from 2008 33 patients with primary breast cancer receiving adjuvant chemotherapy and simultaneous treatment with Iscador was compared with 33 controls without mistletoe therapy. Reductions in quality of life seemed to be smaller during add-on-therapy with mistletoe. Laboratory parameters showed no difference compared to the control group. Mistletoe patients showed better quality of life and a reduction of in the need of symptom relieving glucocorticoid(cortisone) co-treatment.
A study on altogether 10 patients with early stage cervix cancer and healthy volunteers showed that dose-escalation of Iscador reduces the monocyte-related clinical side effects, like temperature increase and skin reactions. The most interesting clinical long-term effect is the bystander stimulation of various memory T cells that might mediate in vivo antitumor and antiinfectious T-cell response under mistletoe-extract immunization.
In three controlled cohort studies with altogether 374 patients, Iscador may have the effect of prolonging overall survival of cervical cancer patients. In the short term, psychosomatic self-regulation increases more markedly under complementary Iscador therapy than under conventional therapy alone.
Grossarth et al found in 2006 that Iscador showed a clinically relevant effect on breast tumour progression as measured by overall survival as well as by the time to recurrences, lymphatic or distant metastases on 244 patients with breast cancer. In the short term, psychosomatic self-regulation increased more markedly under complementary Iscador therapy than under conventional therapy alone.
Ukrain, also called NSC 631570 is an experimental anticancer drug invented by the Ukrainian researcher Wassil Nowicky and tested clinically for the first time in 1978. It is a product that results from a reaction of alkaloids from greater celandine with the classic cancer medicine Thio-TEPA in the presence of hydrochloric acid. Due to legal prosecution of its manufacturer, Wassil Nowicky, it is currently not available. You can read more about the situation on www.ukrin.com.
Ukrain contents mixture of alkaloids. Chelidonine is generally considered the most important one. Chelidonine, like some other celandine alkaloids, is hardly soluble in water. This makes intravenous injections impossible. The preparation of Ukrain together with Thio-TEPA and hydrochloric acid makes the alkaloids water soluble and injectable. addition. It is probable the anti-cancer effect of Ukrain is a result of a combined action of all its constituents. Previously it has been postulated that the active component of Ukrain was a trimeric structure containing three chelidonine molecules connected by a Thiro-thepa skeleton. This has not been confirmed in later investigations.
Ukrain has been investigated in multiple phase I and phase II clinical trials on a large variety of cancer types with very promising results. Ukrain can also have a possible future role in the treatment of Hepatitis C and other viral infections. Click on this link to go to a summary of all the clinical investigations and case reports on Ukrain.
There is an estimated 38,000 species of mushroom, only about 3,000 are edible, about 700 have known medicinal properties, and less than one percent are recognized as poisonous. But even these poisonous mushrooms when properly elaborated in a laboratory are proving to have some outstanding health benefits. Mushrooms have been used in Traditional Chinese Medicine for thousands of years.
Each time we get sick, our immune system weakens and may become more inadequate or subject to malfunction. Selected mushrooms have been effectively used to boost the immune system to fight a host of diseases, including even deadly cancer. Some of the names of these mushrooms are Lions mane, Shiitake, Maitake, Coryolis Versicolor etc.
Several doctors working in cancer clinics for the past 5 years are reporting very positive results in treating every type of cancer with the diluted poison from Death Cap(Amanita Phalloides). Often in a matter of days tumours start to dissolve and patients feel their condition changing. The European laboratory have made it to safe specification without losing its potency and the doctors using the formula have reported no serious side effects, except from some increased bowel activity date This therapy does not affect the activity of somatic cells and works by greatly enhancing the immune system